1
|
Bruneaux E, Iborra F, Trouche-Sabatier SG, Foucan AS, Gras-Aygon C, Poinas G, Rébillard X, Azria D, Trétarre B. [Bladder tumors in the Hérault department: Results of the Hérault tumor registry registration from1987 to 2019]. Prog Urol 2023; 33:974-982. [PMID: 37648602 DOI: 10.1016/j.purol.2023.08.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Revised: 07/10/2023] [Accepted: 08/01/2023] [Indexed: 09/01/2023]
Abstract
OBJECTIVES The Hérault Tumor Registry (RTH) is a general registry qualified by the national committee of registries since 1987. The objective of this study is to present the evolution of the epidemiology of bladder cancer (stage≥T1) in the Hérault department based on data collected by the RTH over a period from 1987 to 2019. MATERIAL AND METHODS We analyzed trends in bladder cancer incidence in Hérault between 1987 and 2019 by sex, age, and stage, as well as mortality trends between 1987 and 2017. For the years 2018-2019, which are the last two years validated by the registry, we described relative frequencies, sex ratio, mean and median age at diagnosis, cumulative risk, stages at diagnosis, pathology data, and primary treatments. Observed and net survival data are analyzed for those diagnosed between 01/01/2000 and 12/31/2015 with a point date of 06/30/2018. RESULTS In 2018-2019, bladder cancer was the 7th most common cancer in Hérault (5th in men and 12th in women) with an incidence sex ratio of 3.9 men to one woman. The mean age at diagnosis was 75.3 years for men and 77.8 years for women. The probability of having bladder cancer before the age of 75 years was 1.68% for a man (1/59) and 0.34% for a woman (1/295). Urothelial carcinomas accounted for 90.7% of cancers. Between 1987 and 2019, bladder cancer incidence TSMs (worldwide standardized rates) decreased by 0.8% per year in men and remained stable in women. Mortality TSMs between 1987 and 2017 followed the same trends with a decrease of 2.2% per year in men and stability in women. For the 3304 bladder cancers diagnosed between 01/01/2000 and 12/31/2015, the observed 5-year survival was 38% (34% in women and 38% in men). CONCLUSIONS Bladder cancer incidence and mortality rates have decreased slightly in men but remain stable in women in the Hérault. Registries collect only a limited number of variables for each patient. In 2018 the Hérault Registry Specialized in Onco-Urology (RHESOU) was created, to have comprehensive data. LEVEL OF EVIDENCE: 4
Collapse
Affiliation(s)
- E Bruneaux
- Département d'urologie, centre hospitalier universitaire Lapeyronie, avenue doyen Gaston-Giraud, 34090 Montpellier, France.
| | - F Iborra
- Département d'urologie, centre hospitalier universitaire Lapeyronie, avenue doyen Gaston-Giraud, 34090 Montpellier, France; Registre des tumeurs de l'Hérault, Montpellier, France
| | | | - A S Foucan
- Registre des tumeurs de l'Hérault, Montpellier, France
| | - C Gras-Aygon
- Registre des tumeurs de l'Hérault, Montpellier, France
| | - G Poinas
- Département d'urologie, clinique Beau Soleil, Montpellier, France
| | - X Rébillard
- Département d'urologie, clinique Beau Soleil, Montpellier, France
| | - D Azria
- Institut national de la santé et de la recherche médicale U1194, institut du cancer, université Montpellier, Montpellier, France
| | - B Trétarre
- Registre des tumeurs de l'Hérault, Montpellier, France; CERPOP, université de Toulouse, institut national de la santé et de la recherche médicale UPS, Toulouse, France
| |
Collapse
|
2
|
Lebret T, Paoletti X, Pignot G, Roumiguié M, Colombel M, Savareux L, Verhoest G, Guy L, Rigaud J, De Vergie S, Poinas G, Droupy S, Kleinclauss F, Courtade-Saïdi M, Piaton E, Radulescu C, Rioux-Leclercq N, Kandel-Aznar C, Renaudin K, Cochand-Priollet B, Allory Y, Nivet S, Rouprêt M. Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial. World J Urol 2023; 41:2381-2388. [PMID: 37480491 PMCID: PMC10465399 DOI: 10.1007/s00345-023-04519-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 07/01/2023] [Indexed: 07/24/2023] Open
Abstract
PURPOSE Cytology and cystoscopy, the current gold standard for diagnosing urothelial carcinomas, have limits: cytology has high interobserver variability with moderate or not optimal sensitivity (particularly for low-grade tumors); while cystoscopy is expensive, invasive, and operator dependent. The VISIOCYT1 study assessed the benefit of VisioCyt® for diagnosing urothelial carcinoma. METHODS VISIOCYT1 was a French prospective clinical trial conducted in 14 centers. The trial enrolled adults undergoing endoscopy for suspected bladder cancer or to explore the lower urinary tract. Participants were allocated either Group 1: with bladder cancer, i.e., with positive cystoscopy or with negative cystoscopy but positive cytology, or Group 2: without bladder cancer. Before cystoscopy and histopathology, slides were prepared for cytology and the VisioCyt® test from urine samples. The diagnostic performance of VisioCyt® was assessed using sensitivity (primary objective, 70% lower-bound threshold) and specificity (75% lower-bound threshold). Sensitivity was also assessed by tumor grade and T-staging. VisioCyt® and cytology performance were evaluated relative to the histopathological assessments. RESULTS Between October 2017 and December 2019, 391 participants (170 in Group 1 and 149 in Group 2) were enrolled. VisioCyt®'s sensitivity was 80.9% (95% CI 73.9-86.4%) and specificity was 61.8% (95% CI 53.4-69.5%). In high-grade tumors, the sensitivity was 93.7% (95% CI 86.0-97.3%) and in low-grade tumors 66.7% (95% CI 55.2-76.5%). Sensitivity by T-staging, compared to the overall sensitivity, was higher in high-grade tumors and lower in low-grade tumors. CONCLUSION VisioCyt® is a promising diagnostic tool for urothelial cancers with improved sensitivities for high-grade tumors and notably for low-grade tumors.
Collapse
Affiliation(s)
| | - Xavier Paoletti
- Institut Curie, Saint Cloud, France
- Université Versailles Saint-Quentin, Université Paris-Saclay, Saint Cloud, France
| | | | - Mathieu Roumiguié
- Urology Department, Centre Hospitalier Universitaire (CHU) Rangueil, IUCT Oncopole, Toulouse, France
| | - Marc Colombel
- Urology Department, Hôpital Edouard Herriot, Lyon, France
| | - Laurent Savareux
- Urology Auvergne Centre, Clinique de la Chataigneraie, Beaumont, France
| | | | - Laurent Guy
- Urology Department of Urology, CHU Gabriel Montpied, Clermont-Ferrand, France
| | | | | | - Grégoire Poinas
- Urology Department, Clinique Beausoleil, Montpellier, France
| | | | | | | | - Eric Piaton
- Centre de Pathologie Est, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Bron, France
| | - Camelia Radulescu
- Service d'Anatomie et Cytologie Pathologiques, Hôpital Foch, Suresnes, France
| | | | | | - Karine Renaudin
- Department of Pathology, CHU Hôtel Dieu, Nantes, France
- Centre de Recherche en Transplantation et en Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France
| | | | - Yves Allory
- Department of Pathology, Institut Curie, Saint-Cloud, France
- Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | | | - Morgan Rouprêt
- Urology Department, GRC n°5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France
| |
Collapse
|
3
|
Cecchi M, Ninot G, Rebillard X, Thuret R, Droupy S, Ayuso D, Poinas G. [Which non pharmacological interventions should be offered to patients treated with androgen deprivation therapy for prostate cancer? A systematic review]. Prog Urol 2023; 33:287-306. [PMID: 37121810 DOI: 10.1016/j.purol.2023.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Revised: 02/24/2023] [Accepted: 03/27/2023] [Indexed: 05/02/2023]
Abstract
AIM Prostate cancer is a frequent disease and one of the main treatments used is androgen deprivation therapy, which is a therapy with disabling side effects. Non-pharmacological interventions (NPIs) are evidenced based, non-invasive interventions on human health. They are classified into five categories (physical, psychological, nutritional, digital, elemental). The NPIs sphere is booming and still remains underused in this context. METHODS A systematic review concerning randomized controlled trials was executed according to the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). We used the "Medline" and "Kalya Research" databases. After searching and selecting eligible publications, we included 37 randomized controlled trials. RESULTS The majority of articles concerned physical NPIs with 30 clinical studies, 3 publications dealt with nutritional NPIs, 2 with psychological NPIs and 2 articles concerned elemental NPIs. No publication about digital NPI was found. All of the studies aimed to manage and improve the side effects of treatment. No elemental NPI has demonstrated benefit. Only one psychological NPI and one nutritional NPI were effective. Five types of physical NPI protocols have shown efficacy. The main benefits related to physical abilities, body composition, osteoporosis, quality of life, fatigue, reduced cardiovascular risk and finally anxiety and depression. CONCLUSION Non-pharmacological interventions, especially physical ones, are effective in managing and reducing the side effects associated with androgen deprivation therapy and should be offered to patients in this context.
Collapse
Affiliation(s)
- M Cecchi
- Urologie, clinique Beau Soleil, 149, rue de la Taillade, 34070 Montpellier, France.
| | - G Ninot
- Institut Desbrest d'épidémiologie et de santé publique (Université de Montpellier-Inserm), 641, avenue du Doyen Gaston-Giraud, 34093 Montpellier, France
| | - X Rebillard
- Urologie, clinique Beau Soleil, 149, rue de la Taillade, 34070 Montpellier, France
| | - R Thuret
- Urologie et transplantation rénale, CHU Lapeyronie, 371, avenue du Doyen Gaston-Giraud, 34090 Montpellier, France
| | - S Droupy
- Urologie andrologie, CHU de Nîmes, 4, rue du Professeur Robert-Debré, 30900 Nîmes, France
| | - D Ayuso
- Urologie, centre hospitalier du Bassin de Thau, 11, boulevard Camille-Blanc, 34200 Sète, France
| | - G Poinas
- Urologie, clinique Beau Soleil, 149, rue de la Taillade, 34070 Montpellier, France
| |
Collapse
|
4
|
Peigné C, Trabelssi M, Poinas G, Segui B, Reis Borges R, Lamy P, Lacombe S, Livrozet M, Rebillard X. Performances diagnostiques du test urinaire Xpert®Bladder Cancer Monitor dans la surveillance de patients atteints de tumeurs de vessie n’infiltrant pas le muscle : résultats intermédiaires d’une étude prospective. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Poinas G, Aujoulat G, Tretarre B, Iborra F, Thuret R, Rizet D, Abdel-Hamid S, Delbos O, Ayuso D, Bringer J, Rébillard X, Azria D, Riou O. Le cancer de la prostate dans le département de l’Hérault : résultats de 30 ans d’enregistrement (1987–2016). Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Poinas G, Murez T, Tretarre B, Thuret R, Rizet D, Delbos O, Abdel-Hamid S, Ayuso D, Bringer J, Rébillard X, Azria D, Iborra F. Tumeurs testiculaires dans le département de l’Hérault : résultats de 30 ans d’enregistrement (1987–2016). Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Trouche-Sabatier SG, Rebillard X, Iborra F, Azria D, Daures JP, Poinas G, Abdo N, Delbos O, Gevorgyan A, Marchal S, Guillon R, Millet I, Lamy PJ, Lauche O, Reis-Borges R, Serre I, Topart D, Tretarre B. [RHESOU (Registry in HErault Specialized in Onco-Urology) : the first French Registry specialized in Onco-Urology. One-year experience]. Prog Urol 2020; 30:1038-1044. [PMID: 33012630 DOI: 10.1016/j.purol.2020.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 08/13/2020] [Accepted: 09/06/2020] [Indexed: 10/23/2022]
Abstract
PURPOSE In 2016, the Herault tumor registry collected 1961cancers in urology (21.4 % from all Herault cancers this year). RHESOU was created to complete RTH' data with specific parameters in onco-urology. The aim of this study is to describe RHESOU and to give some examples with our first results. MATERIAL AND METHODS In November 2018, RHESOU (Registry HErault Specialised in Onco-Urology) was founded with the same registry recommendations. It collects specific oncologic parameters and also complete RTH's data. For each urological cancer, a specific survey with different choices was performed to collect a maximum of data which could be present in patients' file. These surveys were used for urological cancers cases that live in Herault in 2017. RESULTS In 2017, we collected 970 prostate cancers, 581 bladder cancers, 212 kidney cancers, 51 upper excretory tract cancers, 28 testicle cancers and 9 penil cancers. Our urological data collection gives many possibilities to create many requests for detailed analysis in urological cancers. In this article, we reported data from kidney, bladder and prostate cancers. CONCLUSIONS RHESOU is a new tool opened to the different urologic corporations (urologists, pathologists, oncologists, radiotherapists, radiologists) that permits an overview in urological cancers in Herault. Finally, one important aim is that this tool will be adapted when new treatments or new important parameters appear in the years ahead. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
| | - X Rebillard
- Comité de pilotage, Montpellier, France; Clinique Beau Soleil, Montpellier, France
| | - F Iborra
- Comité de pilotage, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - D Azria
- Comité de pilotage, Montpellier, France; Inserm U 1194, ICM, université Montpellier, Montpellier, France
| | - J-P Daures
- Comité de pilotage, Montpellier, France; Clinique Beau Soleil, Montpellier, France; IURC, Montpellier, France
| | - G Poinas
- Comité scientifique du RHESOU, Montpellier, France; Clinique Beau Soleil, Montpellier, France
| | - N Abdo
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - O Delbos
- Comité scientifique du RHESOU, Montpellier, France; Urodoc, Montpellier, France
| | - A Gevorgyan
- Comité scientifique du RHESOU, Montpellier, France; Polyclinique Saint-Privat Boujan sur Libron, Béziers, France
| | - S Marchal
- Comité scientifique du RHESOU, Montpellier, France; Urodoc, Montpellier, France
| | - R Guillon
- Comité scientifique du RHESOU, Montpellier, France; Clinique Beau Soleil, Montpellier, France
| | - I Millet
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - P-J Lamy
- Comité scientifique du RHESOU, Montpellier, France; Imagenome-inovie, Montpellier, France
| | - O Lauche
- Comité scientifique du RHESOU, Montpellier, France; Clinique Clémentville, Montpellier, France
| | - R Reis-Borges
- Comité scientifique du RHESOU, Montpellier, France; Inopath Labosud, Montpellier, France
| | - I Serre
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - D Topart
- Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France
| | - B Tretarre
- Comité de pilotage, Montpellier, France; Registre des tumeurs de l'Hérault, Montpellier, France
| | | |
Collapse
|
8
|
Gas J, Dominique I, Mathieu R, Poinas G, Cuvelier G, Rebillard X, Corbel L. [Radical prostatectomy for prostate cancer, perioperative management by French urologists in 2018]. Prog Urol 2020; 30:541-546. [PMID: 32646841 DOI: 10.1016/j.purol.2020.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 06/17/2020] [Accepted: 06/22/2020] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Prostatectomy (PT) is a common procedure performed by many urologists. In 2018, 20,207 prostatectomies were performed in France, and few studies evaluated the perioperative habits of urologists. As part of writing guidelines for enhanced recovery after surgery (ERAS) we wished to evaluate practice of urologists in their hospital management of a prostatectomy. MATERIEL AND METHODS A questionnaire was sent by Survey Monkey in June and July 2018 to all urologists who are members of the French Association of Urology. RESULTS One hundred and sixty seven urologists (14%) answered the questionnaire, 62% have private practice. The average number of operators per center performing PT was 4, with a median number of 70 interventions (0 to 486) per center in 2018. Open surgery is still gold standard (39.13%), followed by the robot-assisted transperitoneal laparoscopic (34.78%) and standard laparoscopic (24.22%). Alimentation, like first stand-up, was re-established on the first post-operative day, and the average hospital stay was 4±2 nights. The removal of the bladder catheter was most often performed at home by nurse (49.06%), one week after surgery. Only 10.06% of urologists systematically perform a cystography before removal urinary catheter. CONCLUSION The perioperative management of prostatectomy in France is relatively homogeneous, between urologists. The length of hospital stay remains important and could be reduced by proposing an ERAS protocol as has been obtained for cystectomy. LEVEL OF EVIDENCE III.
Collapse
Affiliation(s)
- J Gas
- Département d'urologie, andrologie et transplantation rénale, CHU de Toulouse, Toulouse, France
| | - I Dominique
- Service d'urologie, groupe hospitalier Diaconesses croix saint-Simon, Paris, France
| | - R Mathieu
- Service d'urologie, CHU de Rennes, Rennes, France
| | - G Poinas
- Service d'urologie, clinique Beausoleil, Montpellier, France
| | - G Cuvelier
- Service d'urologie, centre hospitalier de Cornouaille, Quimper, France
| | - X Rebillard
- Service d'urologie, clinique Beausoleil, Montpellier, France
| | - L Corbel
- Service d'urologie, hôpital privé des côtes d'Armor, Plerin, France
| | | |
Collapse
|
9
|
Poinas G, Blache J, Kassab-Chahmi D, Evrard P, Artus P, Alfonsi P, Rébillard X, Beaussier M, Cerantola Y, Coloby P, Drapier É, Houédé N, Masson-Lecomt A, Rouprêt M, Le Normand L, Gamé X, Bosset P, Delaunay L, Fendler J, Ecoffey C, Cuvelier G. Version courte des recommandations de la récupération ameliorée après chirurgie (RAAC) pour la cystectomie : mesures techniques. Prog Urol 2019; 29:63-75. [DOI: 10.1016/j.purol.2018.12.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2018] [Revised: 11/28/2018] [Accepted: 12/01/2018] [Indexed: 12/20/2022]
|
10
|
Poinas G, Long JA, Rébillard X, Descotes JL. Place de la néphrectomie partielle assistée par robot : revue de la littérature à l’heure d’une demande de nomenclature spécifique. Prog Urol 2018; 28:890-899. [DOI: 10.1016/j.purol.2018.08.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2017] [Revised: 08/09/2018] [Accepted: 08/14/2018] [Indexed: 01/20/2023]
|
11
|
Trabelssi M, Poinas G. La protéine C-réactive à j4 postopératoire, un marqueur fiable du risque de complications après cystectomie. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Long JA, Poinas G, Fiard G, Leprêtre M, Delaitre-Bonnin C, Rébillard X, Descotes JL. Prostatectomie radicale laparoscopique robot-assistée : quelles sont les preuves à l’heure d’une demande de nomenclature spécifique ? Prog Urol 2017; 27:146-157. [DOI: 10.1016/j.purol.2016.12.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 11/02/2016] [Accepted: 12/17/2016] [Indexed: 01/08/2023]
|
13
|
Iborra F, Murez T, Millet I, Serre I, Poinas G, Thuret R. Les cancers primitifs de l’urètre. ONCOLOGIE 2014. [DOI: 10.1007/s10269-014-2387-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Murez T, Millet I, Poinas G, Cabaniols L, Fadli S, Guiter J, Iborra F, Robert M, Curros Doyon F, Taourel P, Thuret R. Prédiction par biopsie percutanée du sous-type histologique et du grade de Fuhrman des petits cancers à cellules rénales. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Poinas G, Murez T, Szwarc I, Fadli S, Cabaniols L, Guiter J, Garrigue V, Iborra F, Mourad G, Thuret R. Évaluation à long terme de la transplantation rénale avec transplant à artères multiples. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
16
|
Poncelet P, Poinas G, Corbeau P, Devaux C, Tubiana N, Muloko N, Tamalet C, Chermann JC, Kourilsky F, Sampol J. Surface CD4 density remains constant on lymphocytes of HIV-infected patients in the progression of disease. Res Immunol 1991; 142:291-8. [PMID: 1718020 DOI: 10.1016/0923-2494(91)90078-w] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In an attempt to question the influence of circulating virus, soluble gp120 or CD4 self-reacting antibodies upon results of CD4+ T-cell immunophenotyping in AIDS patients, five anti-CD4 mAb defining several epitopes of the V1 and V2 domains of the CD4 molecule were used to analyse the epitopic density of CD4 on lymphocytes of seropositive patients taken at stages II, III and IV of HIV infection, according to the Centers for Disease Control (CDC, Atlanta) classification. Our results demonstrate that each CD4 epitopic density measured on circulating lymphocytes remains constant at a mean level of 46,000 epitopes per cell whatever the stage of the disease and whatever the serum p25 concentration. These data provide evidence that antibody accessibility to several CD4 epitopes is not altered by putative interactions between CD4 molecules and circulating virus, soluble gp120 or anti-CD4 autoantibodies. If such binding events, as expected, do occur in vivo, they are of too low a magnitude to influence the immunophenotyping. Furthermore, we show that mAb specific for different epitopes in the V1 and V2 domains of the CD4 molecule can be used interchangeably for the biological followup of the CD4+ cell population in blood samples of HIV-infected patients.
Collapse
Affiliation(s)
- P Poncelet
- Laboratoire d'Hématologie, Hôpital de la Conception, Marseille, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|